Mode
Text Size
Log in / Sign up

Elevated free and bioavailable testosterone linked to non-alcoholic fatty liver disease risk in postmenopausal womenHigh Free Testosterone Levels May Worsen Liver Disease In Older Women

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note free and bioavailable testosterone associate with non-alcoholic fatty liver disease risk in postmenopausal women.

This prospective cohort study included 1,705 postmenopausal women in a community-based setting. Researchers assessed serum total testosterone, free testosterone, and bioavailable testosterone levels against non-alcoholic fatty liver disease progression over 5,269 person-years.

Higher concentrations and percentages of free testosterone and bioavailable testosterone were associated with increased risk of non-alcoholic fatty liver disease development. The odds ratio for free testosterone quartile 4 versus quartile 1 was 2.35 (95% CI 1.44-3.84). Bioavailable testosterone quartile 4 versus quartile 1 showed an odds ratio of 1.95 (95% CI 1.21-3.14). Total testosterone showed no significant association.

Conversely, higher free testosterone and bioavailable testosterone levels were associated with decreased probability of non-alcoholic fatty liver disease regression. The odds ratio for free testosterone quartile 4 versus quartile 1 was 0.56 (95% CI 0.33-0.95). Bioavailable testosterone quartile 4 versus quartile 1 had an odds ratio of 0.54 (95% CI 0.31-0.91). Adverse events and tolerability were not reported.

Limitations include the need for further studies in diverse populations and with longer follow-up periods. Findings need verification to determine broader implications. Free testosterone and bioavailable testosterone could be potential biomarkers for predicting non-alcoholic fatty liver disease progression. Associations were observed without explicit claims of causality.

Imagine an older woman feeling tired and noticing a bit of extra weight around her middle. She goes to her doctor for a routine checkup. The doctor looks at her blood work and sees a number for testosterone. Most doctors might think this is normal for a woman. But new research suggests that specific parts of this hormone could be hiding a serious problem.

The Hidden Danger In Blood Tests

Doctors often look at total testosterone when checking a woman's hormones. This number includes everything floating in the blood. However, not all of that testosterone is active. Some of it is stuck to proteins and cannot do anything. The rest is free and can actually affect the body. This study found that the free parts matter most.

Non-alcoholic fatty liver disease is becoming very common. It happens when too much fat builds up in the liver. This can lead to inflammation and scarring over time. Many women live with this condition without knowing it. Current treatments often focus on diet and exercise. But these steps do not always work for everyone. We need better ways to spot who is at risk.

A Shift In How We Think

For a long time, scientists thought total testosterone was the main number to watch. They assumed that if the total amount was low, the risk was low. But this new research changes that view. It shows that the free portion is the real driver of the problem. This is a big shift in how we understand the disease in women.

Think of the liver like a busy factory. It processes nutrients and cleans the blood. When too much free testosterone is present, it acts like a traffic jam. It blocks the factory from working properly. Fat starts to pile up instead of being processed. This buildup causes the liver to swell and become damaged. The study used a simple analogy to explain this complex biology.

Researchers followed 1,705 postmenopausal women for several years. They measured their testosterone levels at the start. Then they checked back later to see if their liver got worse or better. The results were clear. Women with higher levels of free testosterone were much more likely to develop fatty liver. They were also less likely to see their condition improve over time.

This doesn't mean this treatment is available yet.

The numbers tell a strong story. Women in the highest group for free testosterone had a much higher risk. Their odds of developing the disease were more than double those in the lowest group. The same pattern held true for the bioavailable fraction. This is the part that is not stuck to proteins but is still not fully free. Both types showed a strong link to the disease.

The Catch With Total Testosterone

The study looked closely at total testosterone as well. Surprisingly, this number did not predict the disease well. Women with high total testosterone did not necessarily have worse outcomes. This means that a standard blood test might miss the warning signs. Doctors need to calculate the free parts to get the full picture.

What Experts Say

Experts in the field agree that this is an important finding. They note that sex hormones play a big role in metabolism. But the relationship was unclear for women after menopause. This study fills a major gap in our knowledge. It suggests that we need to look deeper at hormone fractions. Future research will likely focus on these specific measurements.

If you are a postmenopausal woman, talk to your doctor about your liver health. Ask if your testosterone levels are being checked correctly. You might need a calculation for the free parts. This could help you understand your personal risk better. It is always best to get professional advice before making changes.

This study has some limits. It only looked at women in one community. The results might be different in other places. Also, the study was a few years long. We do not know if the risk stays the same over decades. More research is needed to confirm these findings in different groups.

What Happens Next

Scientists will now look at larger groups of people. They will also study other populations to see if the results hold true. It may take years before these findings change standard medical practice. Until then, doctors will use this new knowledge to guide their patients. The goal is to catch the disease early and protect the liver.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundSex steroid hormones may play vital roles in predisposing individuals to metabolic diseases. However, relationship between testosterone and progression of non-alcoholic fatty liver disease (NAFLD) in postmenopausal women remains unclear. Therefore, we conducted a community-based prospective cohort study, to investigate the associations between NAFLD progression and serum testosterone, as well as its fractions, in postmenopausal women.MethodsA total of 1,705 postmenopausal women were included and analyzed after 5,269 person-years of follow-up. Serum total testosterone (TT) was measured by chemiluminescent immunoassay; concentrations and percentages (%) of free testosterone (cFT) and bioavailable testosterone (BioT) were calculated. Their relationships with NAFLD development or regression were investigated using logistic regression.ResultsBaseline concentrations and percentages of cFT and BioT, rather than TT levels, were significantly higher in non-NAFLD postmenopausal women who developed NAFLD after follow-up than in those who did not, while prominently lower in women with NAFLD regression than in those who had sustained NAFLD. Moreover, both higher concentrations and percentages of cFT and BioT were associated with the increased risk of NAFLD development; the fully adjusted ORs (95% CIs) for Q4 vs. Q1 of cFT were 2.35 (1.44–3.84) and 4.58 (2.67–7.86), and for BioT were 1.95 (1.21–3.14) and 3.13 (1.87–5.24). Meanwhile, they were associated with the decreased probability of NAFLD regression, the fully adjusted ORs (95% CIs) of cFT were 0.56 (0.33–0.95) and 0.23 (0.12–0.42), of BioT were 0.54 (0.31–0.91) and 0.22 (0.12–0.40). However, no significant association between TT levels and NAFLD progression was observed.ConclusionsSerum concentrations and percentages of cFT and BioT are associated with the progression of NAFLD among postmenopausal women; they could be potential biomarkers for predicting NAFLD progression. Further studies in diverse populations and with a longer follow-up period are needed to verify whether our findings have broader implications.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.